CORE DIAGNOSTICS™

Your Test Result

Case ID	102230167522
Patient Name	BUDDHIKA SUSANTHA BADDAGE
Age/Sex	48 Year /Male
Hospital Location	Colombo, Colombo, Sri Lanka
Hospital Name	Novex Pharmaceuticals Limited, Colombo
Physician Name	Dr. Mahendra Perera
Date & Time of Accessioning	07/10/2023 19:56 Hrs
Date & Time of Reporting	12/10/2023 16:43 Hrs

Result

Report

TEST NAME

ALK

SPECIMEN INFORMATION

Number of Samples Received	Received four paraffin blocks Collected on 05/10/2023 at 00:00 Hrs
Test performed on	WH-2488 F

CLINICAL HISTORY

Moderately differentiated adenocarcinoma colon.

METHODOLOGY

Immunohistochemistry

IMMUNOHISTOCHEMISTRY STUDIES

Marker(Clone)	Result	Image
ALK (D5F3)	NEGATIVE	

COMMENTS

1. Presence of strong granular cytoplasmic staining in tumor cells (any percentage of tumor cells) is considered as positive.
2. Ventana anti- ALK(D5F3) CDX assay is an FDA approved method for qualitative detection of ALK protein in FFPE Non small cell lung carcinoma tissue stained with Benchmark XT or Benchmark Ultra automated staining instrument.It helps in identifying patients who may benefit from treatment with Crizotininb, Ceritinib and Alectininb.

Note: Positive and negative controls are run for each case

MC-2256

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS
AU-ID-2010258

Dr. Shivani Sharma, DCP, DNB
Reg. No. 1906

CORE DIAGNOSTICS™

Case ID	102230167522
Patient Name	BUDDHIKA SUSANTHA BADDAGE
Age/Sex	48 Year /Male
Hospital Location	Colombo, Colombo, Sri Lanka
Hospital Name	Novex Pharmaceuticals Limited, Colombo
Physician Name	Dr. Mahendra Perera
Date & Time of Accessioning	07/10/2023 19:56 Hrs
Date & Time of Reporting	12/10/2023 16:43 Hrs

Result

Report

TECHNICAL NOTE

All immunohistochemistry markers have been evaluated in the context of appropriate positive and negative controls. A result is considered uninterpretable as a result of the type of fixative used (non 10% neutral buffered formalin), time to fixation (> 1 hour), duration of fixation (> 6 hour or < 72 hour), strong decalcification, or inappropriate staining of normal internal or external assay controls. An alternative sample for retesting is then usually recommended.

Disclaimer : These assays have not been validated on decalcified specimens.

REFERENCES

1. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018;13(3):323–358
2. Mino-Kenudson M. Immunohistochemistry in anaplastic lymphoma kinase and proto-oncogene tyrosine-protein kinase ROS. Arch Pathol Lab Med. 2018;142(7):792–793

MC-2256

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS
AU-ID-2010258

Shivani

Dr. Shivani Sharma, DCP, DNB
Reg. No. 1906

Scan to Connect

Question?

Contact us at **+91 124 4615 615**

Toll Free Helpline **+91 8882899999**

CONDITIONS OF REPORTING

1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the bill/test request form.

2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory.

3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.

4. Some tests are referred to other laboratories to provide a wider test menu to the customer.

5. Core Diagnostics Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruction of specimen,which is not attributable to any direct and mala fide act or omission of Core Diagnostics Pvt. Ltd. or its employees. Liability of Core Diagnostics Pvt. Ltd.for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.

This report is the property of CORE Diagnostics. The information contained in this report is strictly confidential and is only for the use of those authorized. If you have received this report by mistake, please contact CORE Diagnostics

CORE Diagnostics (Central Reference Lab) - Gurugram (102)
406, Udyog Vihar, Phase III, Gurgaon-122016

CORE Diagnostics Lab - New Delhi (103)
C-13, Green Park Extension, New Delhi-110016

CORE Diagnostics Lab - Bangalore (105)
1st Floor, KMK Tower, 142 KH Road, Bangalore-560027

CORE Diagnostics Lab - Lucknow (109)
J.S. Tower, Plot No. K-702, Sector-K, Ashiyana,
Near Raj Luxmi Sweets, Lucknow-226012

CORE Diagnostics Lab - Bhubaneswar (108)
Plot No. 249, Near Police Academy, AIIMS Nagar,
Patrapada, Bhubaneswar-751019

CORE Diagnostics Satellite Lab (110)
New Delhi 67, Hargobind Enclave, New Delhi - 110092

CORE Diagnostics and Realab Diagnostics (111)
New Delhi H64, Block H, Bali Nagar, New Delhi, Delhi 110015

CORE Diagnostics Satellite Lab
Guwahati Ground Floor, Honuram Boro Path, Shubham Velocity, GS Road, Dispur, Kamrup Metropolitan
Guwahati, Assam - 781005

The test was processed in Lab 102.